BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With Single de Novo Coronary Artery Lesions - II.

Trial Profile

BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With Single de Novo Coronary Artery Lesions - II.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms BIOFLOW-II
  • Sponsors BIOTRONIK
  • Most Recent Events

    • 30 May 2018 Planned End Date changed from 1 Apr 2017 to 1 Dec 2018.
    • 02 Nov 2017 5-year clinincal results in the total patient cohort as well as in the diabetic and small vessel subgroups presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 30 May 2013 Positive outcome for primary endpoint reported at a late-breaking clinical trials session at the EuroPCR congress, according to a Biotronik media release. Data also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top